Stanford Alzheimer's Disease Research Center Clinical Trials and Research Studies

Studies directly supported by the ADRC

Healthy Brain Aging Study

This is a longitudinal study enrolling individuals with Alzheimer’s disease, Mild Cognitive Impairment, Lewy Body Dementia, Parkinson’s disease, Parkinson’s disease with dementia and healthy volunteers. It is funded by the National Institute of Health and is part of the Alzheimer’s Disease Research Center (ADRC). This study will collect data including medical history, family history and medication. There will be questionnaires to be filled out, cognitive testing and PET/MRI of the brain. This study will follow participants over time.
Active recruiting
Victor Henderson, MD
Status: Open, enrollment ongoing
Research coordinator: Christina Wyss-Coray
650-721 2409

Pacific Udall Center

Sponsor: NIH/NINDS Morris K. Udall Center of Excellence for Parkinson's Disease Research
PI: Tom Montine, MD, PhD
Study status: Open, Enrollment ongoing
Research coordinator: Maria-Lucia Campos


Other studies directed by ADRC-affiliated faculty

Tau PET brain imaging in Parkinson’s disease

Sponsor: NIH/NINDS
PI: Kathleen Poston, MD, MS
Study Status: Actively recruiting
Research coordinator: Marian Shahid, MSc 

Parkinson’s disease Facial Expression Biomarker Study

Sponsor: The Michael J. Fox Foundation for Parkinson’s disease Research
PI: Kathleen Poston, MD, MS
Study status: Actively recruiting
Research coordinator:
Marian Shahid, MSc (650) 723-0060 

Iron as an Imaging Biomarker for Inflammation in Alzheimer’s Disease

The purpose of this study is to learn how iron is potentially involved in Alzheimer’s disease.  We are enrolling individuals with Alzheimer’s disease, individuals with Mild Cognitive Impairment, and healthy volunteers.  You will be asked to complete a 7T MRI and a PET-MRI.
NIH, GE Healthcare
Open, enrollment ongoing
Michael Zeineh, MD
Research Coordinator:
Nicole Mouchawar

Clinical Trials

A Phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group, 18-month study with an open-label extension phase to confirm safety and efficacy of BAN2401 in subjects with early Alzheimer's disease (Clarity AD)

Sponsor: Eisai
: Sharon Sha, MD
: Open for Enrollment
Hanna Balcha   

A randomized, double-blind, placebo-controlled study that will assess the efficacy, safety, and tolerability of 2 dose levels of COR388 oral capsules in subjects with probable AD dementia according to the National Institute on Aging-Alzheimer's Association (NIA-AA) criteria (Gain Study)

Sponsor: Cortexyme
: Sharon Sha, MD
: Open for Enrollment
: Amanda Ng

Clinical Trials Contact